

DAFTAR ISI

HALAMAN JUDUL.....	i
LEMBAR PENGESAHAN.....	ii
PERNYATAAN BEBAS PLAGIASI.....	iv
DAFTAR ISI.....	vii
DAFTAR TABEL.....	ix
DAFTAR GAMBAR.....	x
DAFTAR SINGKATAN.....	xi
INTISARI.....	xiii
ABSTRACT.....	xiv
BAB I PENDAHULUAN.....	1
1.1 Latar Belakang.....	1
1.2 Rumusan Masalah.....	4
1.3 Tujuan Penelitian.....	4
1.4 Manfaat Penelitian.....	4
1.5 Keaslian Penelitian.....	4
BAB II TINJAUAN PUSTAKA.....	7
2.1 Tinjauan Pustaka.....	7
2.1.1 Etiologi.....	7
2.1.2 Epidemiologi.....	9
2.1.3 Patofisiologi.....	12
2.1.4 Histopatologi Kanker Serviks.....	14
2.1.5 Derajat Diferensiasi Tumor.....	15
2.1.6 Stadium Kanker Serviks.....	15
2.1.7 Terapi.....	18
2.1.8 Biomarker Kanker Serviks.....	19
2.1.9 Mekanisme Apoptosis dan Bcl-2.....	19
2.2 Kerangka Teori.....	25
2.3 Kerangka Konsep.....	26
2.4 Hipotesis.....	26
BAB III METODE PENELITIAN.....	27
3.1 Ruang Lingkup Penelitian.....	27
3.2 Tempat dan Waktu Penelitian.....	27

3.3. Jenis dan Rancangan Penelitian.....	27
3.4 Populasi dan Sampel	29
3.4.1 Populasi Target.....	29
3.4.2 Populasi Terjangkau	29
3.4.3 Sampel	29
3.4.4 Cara Sampling	30
3.4.5 Besar Sampel	34
3.5 Variabilitas Penelitian	35
3.5.1 Variabel Bebas	35
3.5.2 Variabel Terikat.....	35
3.5.3 Variabel Luar	35
3.5.4 Definisi Operasional	35
3.6 Alur Penelitian.....	37
3.7 Cara Analisis Data.....	38
3.8 Etika Penelitian.....	38
3.9 Keterbatasan Penelitian	39
BAB IV HASIL DAN PEMBAHASAN.....	40
4.1 Hasil Penelitian.....	40
4.1.1 Karakteristik Dasar Penelitian	41
4.1.2 Analisis Bivariat	42
4.1.3 Analisis Multivariat	45
4.2 Pembahasan	46
4.3. Kelemahan Penelitian	51
BAB V KESIMPULAN DAN SARAN	52
5.1 Kesimpulan.....	52
5.2 Saran.....	52
DAFTAR PUSTAKA.....	53

DAFTAR TABEL

TABEL 1. Keaslian Penelitian	5
TABEL 2. Lesi Ginekologi dan Subtipe HPV (Di Saia and Creasman, 2012)	9
TABEL 3. Prevalensi Kanker di Indonesia (Limpens, 2018)	11
TABEL 4. Pembagian Stadium Kanker Serviks Berdasarkan FIGO 2018	17
TABEL 5. Definisi Operasional	35
TABEL 6. Definisi Operasional	36
TABEL 7. Definisi Operasional	37
TABEL 8. Karakteristik Subyek Penelitian (n=92)	41
TABEL 9. Hubungan antara Ekspresi Protein BCL-2 dengan DerajatDiferensiasi	42
TABEL 10. Hubungan antara Ekspresi Protein BCL-2 dengan Jenis Histopatologi	43
TABEL 11. Hubungan antara Variabel Bebas dengan Variabel Luar	43
TABEL 12. Hubungan antara Derajat Diferensiasi dengan Variabel Luar.....	44
TABEL 13. Hubungan antara Jenis Histopatologi dengan Variabel Luar	45
TABEL 15. Analisis Multivariat Pengaruh antar Variabel Bebas terhadap Variabel Luar	46

DAFTAR GAMBAR

GAMBAR I. Anatomi Serviks dan Squamocolumnar Junction.....	8
GAMBAR II. Struktur Genom HPV 16 dan Aktivitas Transformasi E6 dan E7 .	12
GAMBAR III. Patogenesis Kanker Serviks	13
GAMBAR IV. Jalur Apoptosis Mitokondria (intrinsik)	24
GAMBAR V. Kerangka Teori	25
GAMBAR VI. Kerangka Konsep	26
GAMBAR VII. Jenis Penelitian	28
GAMBAR VIII. Rancangan Penelitian	29
GAMBAR IX. Tradisional Hscore.....	33
GAMBAR XI. Alur Penelitian	37
GAMBAR XII. Populasi Penelitian	40

DAFTAR SINGKATAN

AIF	<i>Apoptosis inducing factor</i>
APAF 1	<i>Apoptotic Protease Activating Factor-1</i>
ATM-ATR	<i>Ataxia-telangiectasia mutated, ATM and Rad3-related</i>
BAD	<i>Bcl-2 Antagonist of Cell Death</i>
Bak	<i>Bcl-2 antagonist/ killer</i>
Bax	<i>Bcl-2 Associated X-protein</i>
Bcl-B	<i>Bcl-2 like protein 10</i>
Bcl-2	<i>B-Cell Lymphoma 2</i>
Bcl-2 L1	<i>Bcl-2 like protein 1</i>
Bcl-xL	<i>B-Cell Lymphoma-extra Large</i>
Bcl-W	<i>Bcl-2 like protein 2</i>
BCL 2L2	<i>Bcl-2 like protein 2</i>
BFL-1	<i>Bcl-2 related protein A1</i>
BH Domain	<i>Bcl-2 homology domain</i>
BID	<i>BH3-interacting domain death agonist</i>
BIK	<i>Bcl-2 interacting killer</i>
BIM	<i>Bcl-2 interacting mediator of cell death</i>
Caspase	<i>Cysteine dependent aspartate directed proteases</i>
CCRT	<i>Concurrent platinum based chemoradiation</i>
CDC	<i>Centers for Disease Control</i>
CDH1	<i>Cadherin1</i>
CDH2	<i>Cadherin2</i>
CDKN2A	<i>Cyclin dependent kinase inhibitor 2A</i>
CD95	<i>Cluster of differentiation 95</i>
CHK2	<i>Checkpoint kinase 2</i>
CI	<i>Confident Interval</i>
C-IAP2	<i>Cellular inhibitor of apoptosis 2</i>
CIN	<i>Cervical intraepithelia neoplasma</i>
CT	<i>Computed tomography</i>
CYFRA 21-1	<i>Cytokeratin-19 fragment</i>
DAB	<i>Diamino Benzidine</i>
DATP	<i>Deoxyadenosine triphosphate</i>
DED	<i>Death Effector Domains</i>
DI	<i>Daerah Istimewa</i>
DIC	<i>Disseminated intravascular coagulation</i>
DISC	<i>Death inducing signaling complex</i>
DNA	<i>Deoxyribonucleic acid</i>
E-cadherin	<i>Epithelial-cadherin</i>
ERK1	<i>Extracellular signal regulated kinases 1</i>
ESMO	<i>European Society for Medical Oncology</i>
FADD	<i>Fas Associated protein with Death Domain</i>
FasL	<i>Fas Ligand</i>
FIGO	<i>The International Federation of Gynecology and Obstetrics</i>

HPV	<i>Human Papiloma Virus</i>
HTR2	<i>Human serotonin receptor</i>
HSCORE	<i>Histological Score</i>
ICU	<i>Intensive Care Unit</i>
IGF2	<i>Insulin like growth factor 2</i>
IHC	<i>Immunohistochemistry</i>
IL	<i>Interleukin</i>
IVP	<i>Intravenous pyelogram</i>
Litbangkes	<i>Badan Penelitian dan Pengembangan Kesehatan</i>
MDM2	<i>Mouse double minute 2</i>
MMP2	<i>Metaloproteinase matriks 2</i>
MOM	<i>Mitochondrial outer membrane</i>
MOMP	<i>Mitochondrial outer membrane permeabilization</i>
MRI	<i>Magnetic Resonance Imaging</i>
MYC	<i>Myelocytomatosis</i>
NACT	<i>Neoadjuvant Chemotherapy</i>
NF-kappa-B	<i>Nuclear factor kappa B</i>
NK cell	<i>Natural Killer cell</i>
Nm23-h1	<i>Nucleoside diphosphate Kinase 1</i>
OS	<i>Overall survival</i>
PA	<i>Patologi anatomi</i>
PAK-2	<i>p21-activated kinase 2</i>
PARP	<i>Poly ADP ribose polymerase</i>
PBS	<i>Phosphate buffered saline</i>
PET	<i>Positron Emission Tomography</i>
PFS	<i>Progression free survival</i>
PKC	<i>Protein kinase C</i>
PRb	<i>Protein Rb</i>
PUMA	<i>p53 upregulated modulator of apoptosis</i>
P53	<i>Tumor protein P53</i>
P65	<i>Tumor protein P65</i>
RADD	<i>Receptor Associated Death Domain</i>
RI	<i>Republik Indonesia</i>
RSUP	<i>Rumah Sakit Umum Pusat</i>
SAMC	<i>S-adenosylmethionine carrier</i>
SCC	<i>Squamous cell carcinoma</i>
USG	<i>Ultrasonografi</i>
TIMP2	<i>Tissue inhibitor of metalloproteinase 2</i>
TRAIL	<i>TNF related apoptosis inducing ligand</i>
TRADD	<i>TNF receptor 1 associated death domain protein</i>
VEGF-C	<i>Vascular endothelial growth factor</i>
WHO	<i>World Health Organization</i>
XIAP	<i>X-linked inhibitor of apoptosis protein</i>